The University of Chicago Header Logo

Connection

Sarah Rodriguez to Intravitreal Injections

This is a "connection" page, showing publications Sarah Rodriguez has written about Intravitreal Injections.
Connection Strength

0.898
  1. Association of Health Insurance Status With Severity and Treatment Among Infants With Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus. 2023 Nov-Dec; 60(6):e75-e78.
    View in: PubMed
    Score: 0.233
  2. Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. Ophthalmic Surg Lasers Imaging Retina. 2020 09 01; 51(9):486-493.
    View in: PubMed
    Score: 0.187
  3. Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. J AAPOS. 2020 06; 24(3):149.e1-149.e5.
    View in: PubMed
    Score: 0.184
  4. Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):337-343.
    View in: PubMed
    Score: 0.172
  5. Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226). Ophthalmology. 2018 10; 125(10):e70-e71.
    View in: PubMed
    Score: 0.082
  6. Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018 11 01; 49(11):893-896.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.